Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of
paramount importance. This study will be a Phase II randomized clinical trial testing
Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism
study to prove biological activity and target engagement in humans with early AD. The
investigators will study up to 55 patients over 52 weeks, with primary outcomes being
Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and
cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an
estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.